Product Description
Mechanisms of Action: PBP Antagonist, Cell Wall Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intramuscular, Intravenous, Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Canada | India | Ireland | Italy | Korea | New Zealand | Pakistan | Peru | Portugal | Sweden | Taiwan | Turkey | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|